Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Monnet

Showing results (31-40 of 72) with videos related to

Pageof 8
Sort By:
Clinical Biochemistry|October 6, 2000
Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignanciesC Fuhrman, J C Duche, C Chouaid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1992
Extensive small-cell lung cancer. A randomized comparison of two chemotherapy programs with early crossover in instances of failure. Association pour le Traitement des Tumeurs Intra-Thoraciques (ATTIT)I Monnet, P Chariot, E Quoix, et al.
Arthritis and Rheumatism|April 1, 1994
Determination of the blood lactate:pyruvate ratio as a noninvasive test for the diagnosis of zidovudine myopathyP Chariot, I Monnet, M Mouchet, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Cisplatin and continuous infusion vindesine and 5-fluorouracil in non-small cell lung cancer (NSCLC) (ATTIT 002). ATTIT (Association pour le Traitment des Tumeurs Intra-Thoraciques)M Riggi, E Cvitkovic, H de Cremoux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2011
Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)F Barlesi, R Gervais, H Lena, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1996
Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2aP Soulié, P Ruffié, L Trandafir, et al.
The New England Journal of Medicine|December 16, 1993
Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancerR Arriagada, T Le Chevalier, J P Pignon, et al.
International Journal of Cancer|September 30, 1993
In vitro effects of recombinant human interferon gamma on human mesothelioma cell linesL Zeng, A Buard, I Monnet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2009
The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinomaD Planchard, J Domont, E Taranchon, et al.
Journal of the National Cancer Institute|February 1, 1995
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remissionR Arriagada, T Le Chevalier, F Borie, et al.
Pageof 8

Showing results (31-40 of 72) with videos related to

Sort By:
Pageof 8
Clinical Biochemistry|October 6, 2000
Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignanciesC Fuhrman, J C Duche, C Chouaid, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|December 1, 1992
Extensive small-cell lung cancer. A randomized comparison of two chemotherapy programs with early crossover in instances of failure. Association pour le Traitement des Tumeurs Intra-Thoraciques (ATTIT)I Monnet, P Chariot, E Quoix, et al.
Arthritis and Rheumatism|April 1, 1994
Determination of the blood lactate:pyruvate ratio as a noninvasive test for the diagnosis of zidovudine myopathyP Chariot, I Monnet, M Mouchet, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1993
Cisplatin and continuous infusion vindesine and 5-fluorouracil in non-small cell lung cancer (NSCLC) (ATTIT 002). ATTIT (Association pour le Traitment des Tumeurs Intra-Thoraciques)M Riggi, E Cvitkovic, H de Cremoux, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 16, 2011
Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01)F Barlesi, R Gervais, H Lena, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1996
Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma. Report of a phase I-II study of weekly cisplatin/interferon alfa-2aP Soulié, P Ruffié, L Trandafir, et al.
The New England Journal of Medicine|December 16, 1993
Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancerR Arriagada, T Le Chevalier, J P Pignon, et al.
International Journal of Cancer|September 30, 1993
In vitro effects of recombinant human interferon gamma on human mesothelioma cell linesL Zeng, A Buard, I Monnet, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|March 20, 2009
The NER proteins are differentially expressed in ever smokers and in never smokers with lung adenocarcinomaD Planchard, J Domont, E Taranchon, et al.
Journal of the National Cancer Institute|February 1, 1995
Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remissionR Arriagada, T Le Chevalier, F Borie, et al.
Pageof 8